Finanzen von Petmed Express Inc (PETS)PETSPetmed Express Inc

PetMed Express, Inc. (PETS) generates its revenue through a diversified portfolio of business segments. Currently, the largest contributor to its top-line growth is Reorder sales, accounting for 80.1% of total sales, equivalent to $32.84M. Other significant revenue streams include New order sales and Membership fees. Understanding this composition is critical for investors evaluating how PETS navigates market cycles within the Drug Retailers industry.

Evaluating the bottom line, PetMed Express, Inc. maintains a gross margin of 22.39%. This metric reflects the company's pricing power and manufacturing efficiency. Further down the income statement, the operating margin stands at -15.19%, while the net margin is -14.98%. These profitability ratios, combined with a Return on Equity (ROE) of -78.58%, provide a clear picture of how effectively PETS converts its operational activities into shareholder value.

In the context of the broader market, PETS competes directly with industry leaders such as SPWH and VRM. With a market capitalization of $39.56M, it holds a significant position in the sector. When comparing efficiency, PETS's gross margin of 22.39% stands against SPWH's 29.59% and VRM's 51.75%. Such benchmarking helps identify whether PetMed Express, Inc. is trading at a premium or discount relative to its financial performance.

PetMed Express has shown declining revenue, with total revenue decreasing from $58,044,000 in Q2 2025 to $40,015,000 in Q1 2027. The gross margin has also declined from 29.49% to 22.39% over the same period, indicating deteriorating profitability.